Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX) announced continued progress of the Company's program to develop nucleotide prodrug inhibitors for the treatment ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE